Garcia-Pavia, PabloRapezzi, ClaudioAdler, YehudaArad, MichaelBasso, CristinaBrucato, AntonioBurazor, IvanaCaforio, Alida L. P.Damy, ThibaudEriksson, UrsFontana, MariannaGillmore, Julian D.Gonzalez-Lopez, EstherGrogan, MarthaHeymans, StephaneImazio, MassimoKindermann, IngridKristen, Arnt V.Maurer, Mathew S.Merlini, GiampaoloPantazis, AntonisPankuweit, SabineRigopoulos, Angelos G.Linhart, Ales2026-02-242026-02-242021-04-23Eur J Heart Fail. 2021 Apr;23(4):512-526.https://hdl.handle.net/20.500.12105/27266P.G.P. reports grant support from Institutode Salud Carlos III (PI20/01379); speaking fees from Pfizer, Eidos,Alnylam, and Akcea; consulting fees from Pfizer, Eidos, Neuroin-mmune, Alnylam, Prothena and Akcea; research support to hisinstitution from Pfizer, Eidos and Alnylam. C.R. reports speakingfees from Pfizer, Alnylam, and Akcea; consulting fees from Pfizer,Alnylam, Prothena and Akcea; institutional research grants fromPfizer. M.A. reports receiving an advisory board fee and a researchgrant from Pfizer and from Sanofi Genzyme. U.E. reports con-sulting fees and grant support from Pfizer and Sanofi; institutionalgrants from Pfizer. M.F. is supported by a British Heart Founda-tion Intermediate Clinical Research Fellowship (FS/18/21/33447)and reports consulting fees from Pfizer, Akcea, Ionis, Alnylam,Alexion, Sanofi and research grant from Pfizer. J.D.G. reports con-sulting and speaking fees from Pfizer, Akcea, Alnylam, and Eidos.E.G.L. reports grant support from Instituto de Salud Carlos III(PI18/0765); speaking fees from Pfizer and Alnylam; consulting feesfrom Pfizer and Proclara; research support to her institution fromPfizer, Eidos and Alnylam. M.G. reports grant/clinical trial supportfrom Alnylam, Eidos, Prothena, and Pfizer. I.K. reports speakingfees from Akcea Therapeutics Germany and Pfizer; consulting feesfrom Akcea Therapeutics Germany. A.V.K. reports consulting feesfrom Pfizer, Akcea, Alnylam, and Neurimmune and speaking feesfrom Pfizer, Akcea, and Alnylam. M.S.M. reports grant support fromNational Institutes of Health [R01HL139671-01], [R21AG058348]and [K24AG036778], consulting income from Pfizer, GSK, EIdos,Prothena, Akcea and Alnylam, and institution received clinical trialfunding from Pfizer, Prothena, Eidos and Alnylam. A.G.R. reportshonoraria for presentations from AstraZeneca. A.L. reports speak-ing fees from Pfizer; consulting fees from Pfizer, Alnylam. All otherauthors have nothing to disclose.engVoREuropean Journal of Heart Failureopen access